Pharma stocks are down to expected tariff on generics. This is opportunity to buy Cos with diversified portfolios & lower reliance to US generics...
ICICID says the US' Biosecure Act which seeks to restrict Chinese biotech cos operating in the US could provide a significant opportunity for...
Divi's has expertise in custom synthesis & excels in tailoring synthesis processes. It has a remarkable track record of securing recurring...
"We are delighted that investors are selling Divi's Labs. We are buying it on a daily basis": Saurabh Mukherjea has explained that no other Indian...
I made a trade in DIVISLAB which enables me to buy the stock at Rs. 3344 even though the CMP is 3660. DIVISLAB is acknowledged by all experts as...
Separate names with a comma.
